Enrolling by invitationPhase 2NCT06066580

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Studying Becker muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Edgewise Therapeutics, Inc.
Principal Investigator
Joanne M. Donovan, MD, PhD
Edgewise Therapeutics, Inc.
Intervention
Sevasemten(drug)
Enrollment
260 enrolled
Eligibility
MALE
Timeline
20232029

Study locations (30)

Collaborators

Medpace, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06066580 on ClinicalTrials.gov

Other trials for Becker muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Becker muscular dystrophy

← Back to all trials